Boston Scientific Co. (NYSE:BSX) Stake was raised by Resonant Capital Advisors LLC

Resonant Capital Advisors LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 14.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,781 shares of the medical equipment provider’s stock after purchasing an additional 484 shares during the period. Resonant Capital Advisors LLC’s holdings in Boston Scientific were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have recently made changes to their positions in BSX. Triad Wealth Partners LLC acquired a new position in Boston Scientific in the second quarter valued at about $26,000. First Foundation Advisors acquired a new stake in shares of Boston Scientific in the first quarter valued at $25,000. Eagle Bay Advisors LLC boosted its position in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 309 shares during the period. Lynx Investment Advisory purchased a new stake in Boston Scientific in the second quarter valued at about $30,000. Finally, RiverPark Advisors LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at approximately $30,000. Institutional investors and hedge funds own 89.07% of the company’s shares.

Changes in Analyst Ratings

Several research firms have recently commented on BSX. Mizuho boosted their target price on shares of Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, May 15th. Truist Financial upped their target price on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Barclays lifted their price objective on Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. Evercore ISI boosted their price target on Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. raised their target price on Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.24, based on data from MarketBeat.

See the latest stock analysis on BSX

Insider buying and selling

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares in the company, valued at approximately $2,978,734.56. The sale was disclosed in a filing with the SEC, which is available at this link. 0.50% of shares are owned by company insiders.

Boston Scientific shares rose 1.4%

BSX opened at $81.79 on Tuesday. The stock has a market cap of $119.99 billion, a price-to-earnings ratio of 68.73, a P/E/G ratio of 2.71 and a beta of 0.78. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $82.10. The company has a 50-day moving average of $77.05 and a 200-day moving average of $73.14. The company has a current ratio of 1.61, a quick ratio of 1.14, and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX – Get Your Free Report ) last announced its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. In the same quarter last year, the company earned $0.53 per share. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Science Profile

(Free Report)

Boston Scientific Corporation develops, manufactures and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices for the diagnosis and treatment of gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, electrocautery-enhanced stents and delivery systems, direct visualization systems, digital catheters and single-use duodenoscopes; devices for the treatment of urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, disposable flexible digital ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber and hydrogel systems; and devices for the treatment of neurological movement disorders and chronic pain management, such as the spinal cord stimulation system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools and the deep stimulation system the brain.

Read more

Want to see what other hedge funds own BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Boston Scientific Co. (NYSE:BSX – Free Report).

Get news and reviews for Boston Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Boston Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.